A phase I study of ACE-2494 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs ACE 2494 (Primary)
- Indications Musculoskeletal disorders
- Focus Adverse reactions
- 19 Sep 2017 The company expects to initiate this clinical trial in late 2017, accoding to an Acceleron Pharma media release.
- 03 Nov 2016 Planned initiation date changed from 1 Dec 2016 to 1 Jun 2017, as per an Acceleron Pharma media release stating that the company plans to initiate this trial in mid-2017.
- 04 Aug 2016 According to a company media release, Acceleron plans to initiate this study in the first half of 2017.